Skip to main content
Advertisement
Advertisement

ELVN

ELVN logo

Enliven Therapeutics, Inc. Common Stock

46.09
USD
Sponsored
-2.10
-4.36%
Sep 23, 16:00 UTC -4
Closed
exchange

After-Market

46.09

-0.01
-0.01%

ELVN Earnings Reports

Positive Surprise Ratio

ELVN beat 17 of 25 last estimates.

68%

Next Report

Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.44
Implied change from Q2 26 (Revenue/ EPS)
--
/
-10.20%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+37.50%

Enliven Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 05, 2026, ELVN reported earnings of -0.49 USD per share (EPS) for Q2 26, missing the estimate of -0.40 USD, resulting in a -20.63% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.95% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.44 USD, with revenue projected to reach -- USD, implying an decrease of -10.20% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Enliven Therapeutics, Inc. Common Stock reported EPS of -$0.49, missing estimates by -20.63%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.95%, changed from $59.70 before the earnings release to $60.27 the day after.
The next earning report is scheduled for Nov 10, 2026.
Based on 7 analysts, Enliven Therapeutics, Inc. Common Stock is expected to report EPS of -$0.44 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement